The company is creating large versatile multi-product facilities, upgrading its manufacturing standards, covering improvements in the manufacturing facility, design and development of total quality systems, constructing modern analytical laboratory as well as training personnel for an in-depth understanding of daily practices according to regulatory requirements. These improvements are expected to lead to a US FDA approval.

MARKSANS addresses the future with robust revenue drivers, its principal products comprise Ciprofloxacin, Enrofloxacin and Ranitidine, addressing large and relevant therapeutic spaces; Ciprofloxacin addresses the antibiotic therapeutic segment; Enrofloxacin addresses the anti-microbial segment while Ranitidine addresses the anti-ulcerant segment.

MARKSANS has designed an aggressive roadmap to drive growth two-fold.

It intends to set up a robust platform to deliver services over the entire value chain of drug discovery and development.

MARKSANS possesses adequate capacity to service the growing needs of the future with two large multi-products and versatile API manufacturing units at Kurkumbh (Pune, India), benchmarked with cGMP standards and leading to a probable US FDA approval in the foreseeable future.

MARKSANS has strengthened its competitive position to succeed in the future, its low cost, high quality and adequate scale (it is India's second largest manufacturer of Ciprofloxacin) have helped it emerge as a supplier of choice to reputed pharmaceutical companies.

The company plans to upgrade its analytical lab and pilot plant facilities to offer chemical synthesis and process development-related research services to global pharmaceutical companies At Marksans Pharma Ltd., such a strategy will enable the company to evolve from transactions to relationships in a time of rapid change.